Review: MAFLD prevalence in children and adolescents

Authors: Ramírez-Mejía MM, Díaz-Orozco LE, Barranco-Fragoso B, et al.
Published in Med Sci Monit 2021
MAFLD is the most common cause of chronic liver disease in children and adolescents. The risk factors for MAFLD may be prenatal, such as genetic factors, or postnatal, such as obesity and insulin resistance. MAFLD is increasingly recognized in children and adolescents...
Read More

MAFLD or NAFLD: reasons and relevance of a single-letter change

Authors: Yilmaz Y, Byrne CD, Musso G.
Published in Expert Rev Gastroenterol Hepatol 2021
Recently, a consensus recommended 'metabolic (dysfunction) associated fatty liver disease' as a more appropriate name to describe fatty liver disease associated with metabolic dysfunction (MAFLD). This single-letter change in the NAFLD acronym suggests that the old acronyms should be abandoned...
Read More

From NAFLD to MAFLD: a premature change in terminology

Authors: Younossi ZM, Rinella ME, Sanyal AJ, et al.
Published in Hepatology 2021
Despite the substantial gains in our understanding of NAFLD/NASH over the past 2 decades, there has been some dissatisfaction with the terminology “non-alcoholic” which overemphasises “alcohol” and underemphasises the predisposing metabolic risk factors. The term MAFLD is still suboptimal, leaving a great deal of ambiguity...
Read More

NAFLD as a metabolic disease, a review

Authors: Cariou B, Byrne CD, Loomba R, et al.
Published in Diabetes Obes Metab 2021
A systematic literature review to identify recent epidemiological, biomarker, genetic and clinical evidence that expands our understanding of NAFLD as a metabolic disorder was performed by B. Cariou et al. (Inserm, CNRS, France). It appears that here is a growing body of evidence on the links between NAFLD/NASH pathogenesis and mechanisms of metabolic dysfunction...
Read More

Sequential combination of NIS-4, MACK-3, and FAST scores

Authors: Zhou YJ, Zheng KI, Targher G, et al.
Published in Lancet Gastroenterol Hepatol 2021
For Y. J. Zhou, et al., there is an urgent need to identify patients who are at risk of developing NASH. Traditional, non-invasive tests have been developed to identify either NASH or advanced fibrosis. However, these tests do not accurately detect patients who are at risk of NASH. Harrison et al. developed and validated the NIS4 test that provides...
Read More

NAFLD: a year in review

Authors: Abdelmalek MF.
Published in Nat Rev Gastroenterol Hepatol 2021
he field of NAFLD and its progressive form, NASH, has, despite the challenges of the COVID-19 pandemic, continued to rapidly evolve in 2020. There have been substantial advances in NAFLD mechanisms, diagnostics, and treatment. Key developments include the identification of a multiparametric cellular and tissue signature to define disease progression...
Read More

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

Authors: Eslam M, Sanyal AJ, George J, et al.
Published in Gastroenterology 2020
The exclusion of other chronic liver diseases including “excess” alcohol intake are usually necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, “positive criteria” to diagnose the disease are required. A panel of international experts from 22 countries...
Read More